BlackRock’s abrdn Life Sciences Investors HQL Stock Holding History

BlackRock’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-287	Closed	-$4.67K	–	5788
2026 Q1	$4.67K	Buy	+287	New	+$4.8K	﹤0.01%	5464
2020 Q1	–	Sell	-13	Closed	–	–	5005
2019 Q4	$0	Buy	+13	New	+$213	﹤0.01%	5014

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

BlackRock's HQL Position: Q2 2026 in Review

BlackRock sold out of abrdn Life Sciences Investors (HQL) in Q2 2026, closing a stake of 287 shares — an estimated $4.67K sold.

BlackRock first reported a position in HQL in Q4 2019 and held it in 2 quarters. The position peaked at $4.67K in Q1 2026. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

BlackRock reported no remaining abrdn Life Sciences Investors position as of Q2 2026 after selling out during the quarter.
BlackRock sold 287 abrdn Life Sciences Investors shares in Q2 2026, an estimated $4.67K.
BlackRock first reported a position in abrdn Life Sciences Investors in Q4 2019 and held it in 2 quarters.
BlackRock's abrdn Life Sciences Investors position peaked at $4.67K in Q1 2026.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.